Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 14 | 2021 | 763 | 2.050 |
Why?
|
| Glioblastoma | 9 | 2017 | 255 | 1.470 |
Why?
|
| Glioma | 6 | 2021 | 285 | 1.310 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2012 | 311 | 0.850 |
Why?
|
| Subarachnoid Hemorrhage, Traumatic | 1 | 2012 | 3 | 0.430 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2021 | 1313 | 0.430 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2012 | 931 | 0.350 |
Why?
|
| ErbB Receptors | 2 | 2011 | 486 | 0.310 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2007 | 153 | 0.290 |
Why?
|
| Drug Therapy | 1 | 2005 | 69 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 5 | 2011 | 1379 | 0.250 |
Why?
|
| Bevacizumab | 6 | 2021 | 281 | 0.230 |
Why?
|
| Dacarbazine | 2 | 2013 | 102 | 0.210 |
Why?
|
| Re-Irradiation | 1 | 2021 | 15 | 0.200 |
Why?
|
| Salvage Therapy | 2 | 2010 | 233 | 0.170 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 301 | 0.170 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 18 | 0.150 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 35 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2007 | 292 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2006 | 3264 | 0.140 |
Why?
|
| Cerebral Cortex | 3 | 1990 | 586 | 0.140 |
Why?
|
| Neurosurgical Procedures | 2 | 2007 | 212 | 0.130 |
Why?
|
| Paraneoplastic Syndromes, Nervous System | 1 | 2015 | 9 | 0.130 |
Why?
|
| Humans | 18 | 2021 | 85796 | 0.120 |
Why?
|
| Male | 13 | 2017 | 40654 | 0.120 |
Why?
|
| Neoplasm Staging | 3 | 2010 | 1938 | 0.120 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 2360 | 0.120 |
Why?
|
| Graft Rejection | 3 | 1990 | 1068 | 0.120 |
Why?
|
| Survival Analysis | 2 | 2007 | 1532 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2007 | 1677 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 302 | 0.120 |
Why?
|
| Neurology | 1 | 2014 | 69 | 0.110 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 18 | 0.110 |
Why?
|
| Treatment Outcome | 6 | 2011 | 7831 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 645 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2012 | 138 | 0.100 |
Why?
|
| Middle Aged | 8 | 2017 | 24742 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2013 | 328 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 787 | 0.100 |
Why?
|
| Snake Venoms | 1 | 2010 | 10 | 0.100 |
Why?
|
| Neural Stem Cells | 1 | 2011 | 58 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 1076 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2014 | 360 | 0.090 |
Why?
|
| Brain Tissue Transplantation | 1 | 1990 | 5 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2007 | 2213 | 0.090 |
Why?
|
| Antigens, Ly | 1 | 1990 | 37 | 0.090 |
Why?
|
| Prognosis | 2 | 2007 | 3639 | 0.090 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 95 | 0.090 |
Why?
|
| Lymphocyte Depletion | 1 | 1990 | 97 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 261 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2011 | 235 | 0.090 |
Why?
|
| Students, Medical | 1 | 2014 | 386 | 0.080 |
Why?
|
| Female | 13 | 2017 | 44218 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2009 | 2438 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1990 | 272 | 0.080 |
Why?
|
| Nerve Tissue | 1 | 1987 | 8 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2007 | 170 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 175 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 2262 | 0.070 |
Why?
|
| Histocompatibility | 1 | 1987 | 71 | 0.070 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 117 | 0.070 |
Why?
|
| Gene Amplification | 1 | 2006 | 131 | 0.070 |
Why?
|
| Cognition | 1 | 2011 | 570 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 178 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 468 | 0.070 |
Why?
|
| Multigene Family | 1 | 2006 | 202 | 0.070 |
Why?
|
| Expert Testimony | 1 | 2005 | 46 | 0.070 |
Why?
|
| United States | 3 | 2017 | 6582 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2007 | 272 | 0.060 |
Why?
|
| Camptothecin | 2 | 2009 | 189 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 812 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 3366 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1760 | 0.060 |
Why?
|
| Protein Binding | 1 | 2006 | 1462 | 0.050 |
Why?
|
| Survival Rate | 3 | 2011 | 1849 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 636 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2583 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 850 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 3 | 1990 | 1060 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 1200 | 0.050 |
Why?
|
| Fatigue | 1 | 2021 | 174 | 0.050 |
Why?
|
| Adult | 7 | 2015 | 25522 | 0.040 |
Why?
|
| Models, Biological | 1 | 2006 | 1749 | 0.040 |
Why?
|
| Aged | 6 | 2017 | 18161 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 4160 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 412 | 0.040 |
Why?
|
| Cerebral Ventricles | 2 | 1990 | 76 | 0.040 |
Why?
|
| Mice, Inbred CBA | 2 | 1987 | 52 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2017 | 201 | 0.040 |
Why?
|
| Brain | 1 | 2006 | 2219 | 0.040 |
Why?
|
| Skin Transplantation | 2 | 1987 | 172 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 593 | 0.030 |
Why?
|
| Young Adult | 3 | 2014 | 5961 | 0.030 |
Why?
|
| Mutation | 1 | 2006 | 3978 | 0.030 |
Why?
|
| Neoplasms | 1 | 2010 | 2895 | 0.030 |
Why?
|
| Isaacs Syndrome | 1 | 2015 | 2 | 0.030 |
Why?
|
| Syringomyelia | 1 | 2015 | 14 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2010 | 429 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 836 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 561 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 985 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 170 | 0.030 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2015 | 122 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 912 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 200 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 702 | 0.030 |
Why?
|
| Personnel Selection | 1 | 2014 | 59 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 1581 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 898 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1999 | 1076 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 1999 | 1052 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 2738 | 0.020 |
Why?
|
| Mice | 3 | 1990 | 11439 | 0.020 |
Why?
|
| H-2 Antigens | 1 | 1990 | 58 | 0.020 |
Why?
|
| Thymectomy | 1 | 1990 | 31 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 269 | 0.020 |
Why?
|
| Curriculum | 1 | 2014 | 542 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 1990 | 148 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1990 | 307 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 502 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 486 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 5178 | 0.020 |
Why?
|
| Macrophage-1 Antigen | 1 | 1987 | 17 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1987 | 103 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 1990 | 997 | 0.020 |
Why?
|
| Necrosis | 1 | 1987 | 204 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1987 | 159 | 0.020 |
Why?
|
| Chicago | 1 | 2010 | 1378 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2014 | 1011 | 0.020 |
Why?
|
| Animals | 3 | 1990 | 26652 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 3591 | 0.010 |
Why?
|
| Inflammation | 1 | 1987 | 923 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1987 | 1200 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1999 | 79 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 120 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1999 | 165 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 1999 | 125 | 0.010 |
Why?
|
| Logistic Models | 1 | 1999 | 1179 | 0.010 |
Why?
|